Form 4: CCRN Executive Karen Mote Receives 8,095 Restricted Shares

Cross Country Healthcare executive Karen Mote was granted 8,095 restricted shares of common stock, vesting over three years, following a terminated merger agreement.

Summary

• Karen Mote, President of Cross Country Locums, acquired 8,095 restricted shares of Cross Country Healthcare Inc. (CCRN) common stock.
• The transaction date for this grant is December 18, 2025.
• These restricted shares will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028.
• The Compensation Committee of the Company's Board of Directors approved the grant date of December 18, 2025, which was adjusted from an earlier planned date of March 31, 2025.
• This adjustment followed the termination of a merger agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.
• After this transaction, Karen Mote beneficially owns 32,407 shares of common stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a key executive is a positive for retention and alignment. However, the underlying reason for the adjusted grant date—a terminated merger agreement—introduces a degree of uncertainty or a negative strategic event, balancing the overall sentiment.

Positives

• The grant of 8,095 restricted shares to a key executive like Karen Mote aligns executive incentives with long-term shareholder value.
• The three-year vesting schedule promotes executive retention and sustained performance.

Negatives

• The change in grant date from March 31, 2025, to December 18, 2025, was due to a terminated merger agreement, which could indicate a failed strategic initiative or unexpected challenges.

Risks

• The termination of the merger agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025, suggests potential strategic or operational challenges that led to the deal's collapse, which could impact future company performance.

Future Outlook

The restricted shares will vest in three installments on December 18, 2026, March 31, 2027, and March 31, 2028, aligning future executive incentives with long-term company performance. The subsequent vesting dates are set to coincide with previously granted RSAs.

Industry Context

The grant of restricted stock awards is a common practice in the healthcare staffing industry to incentivize and retain key executives. The termination of a merger agreement, however, could signal a shift in strategic direction or market conditions within the competitive healthcare services sector.

Comparison to Industry Standards

• The grant of restricted stock to executives is a standard compensation practice across industries, including healthcare staffing, to align management interests with shareholder value.
• The three-year vesting schedule is typical for long-term incentive plans, comparable to practices at peers like AMN Healthcare Services (AMN) or HealthEquity (HQY) for executive retention.
• The specific number of shares granted would need to be benchmarked against similar roles and company size within the healthcare staffing sector to assess its competitiveness, but the filing does not provide enough detail for a direct comparison to specific projects or results.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value, but the terminated merger agreement could raise questions about strategic execution.
• Employees: The executive's continued incentive through RSAs may signal stability in leadership, but the merger termination could create uncertainty.

Next Steps

• First installment of restricted shares will vest on December 18, 2026.
• Second installment of restricted shares will vest on March 31, 2027.
• Third installment of restricted shares will vest on March 31, 2028.

Key Dates

Recommendation

This Form 4 primarily details a routine executive equity grant, which is a standard practice for executive retention and incentive alignment. While the grant itself is a neutral to slightly positive event, the underlying context of a terminated merger agreement, which led to the adjusted grant date, introduces a degree of uncertainty regarding the company's strategic direction. Without further information on the reasons for the merger termination or its financial implications, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting more comprehensive strategic updates.

Keywords

Cross Country Healthcare, CCRN, Karen Mote, Restricted Stock Award, RSA, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Merger Termination